OakChart

Utah Medical Products Inc

UTMDHealthcare·Medical Instruments & Supplies·USA·Micro·NASD·Nov 11 • 2:49 PM ET

73.32+0.46 (0.63%)
2026-11-11 20:49 CET
Market cap
207.58 USD m
Revenue, TTM
34.92 USD m
Net income, TTM
10.64 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
3.34
P/E
21.95
Compare

Price

UTMD against its 20, 50 and 200-day averages
2050200
65.0070.0075.0057K114KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26UTMDclose 73.3220-day 72.4350-day 72.96200-day 68.4873.3252w high

4.6% under the 52-week high of 76.89 on 22 Sep 2026. 52-week low 53.66 on 20 Nov 2025. Last 15 sessions, 14.9% high to low

Profile

UTMD
52-week range, 85% of the way up
53.6676.89

Utah Medical Products, Inc. engages in the manufacturing, developing, and marketing of disposable and reusable medical devices. It focuses on the healthcare of women and babies. The firm's products are used for blood pressure monitoring and blood collection, electrosurgery, gynecology, neonatal critical care, perinatology, and urology. The company was founded on April 21, 1978 and is headquartered in Midvale, UT.

IndexRUT
Employees183
IPOMar 08, 1999
Beta0.40
ATR, 14d1.75
Rel volume0.42
Short float5.73%
Insider own7.19%
Inst own81.70%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap208.89M
Enterprise Value123.87M
Income10.64M
Sales34.92M
Book/sh38.83
Cash/sh29.90
Dividend Est.-
Dividend TTM1.24 (1.69%)
Dividend Ex-DateDec 17, 2026
Dividend Gr. 3/5Y1.68% 1.89%
Payout35.17%
Employees183
IPOMar 08, 1999

Ratios

P/E21.95
Forward P/E-
PEG-
P/S5.98
P/B1.89
P/C2.45
P/FCF18.24
EV/EBITDA9.84
EV/Sales3.55
Quick Ratio19.00
Current Ratio21.23
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)3.34
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-8.33% 3.45%
Sales past 3/5Y-9.68% -1.80%
EPS Y/Y TTM-12.28%
Sales Y/Y TTM-9.62%
EPS Q/Q6.81%
Sales Q/Q-12.14%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own7.19%
Insider Trans0.49%
Inst Own81.70%
Inst Trans0.92%
ROA8.50%
ROE8.81%
ROIC8.62%
Gross Margin54.69%
Oper. Margin30.49%
Profit Margin30.48%
SMA201.22%
SMA500.50%
SMA2007.07%
Trades-

Technical

Shs Outstand3.18M
Shs Float2.64M
Short Float5.73%
Short Ratio4.15
Short Interest0.15M
52W High76.89 -4.64%
52W Low53.66 36.64%
Volatility2.89% 2.25%
ATR (14)1.75
RSI (14)53.47
Beta0.40
Rel Volume0.42
Avg Volume36.49K
Volume12,761

Performance

Perf Week1.24%
Perf Month-1.86%
Perf Quarter1.69%
Perf Half Y14.47%
Perf YTD31.02%
Perf Year28.16%
Perf 3Y-7.19%
Perf 5Y-29.19%
Perf 10Y14.87%
Recom1.00
Target Price65.23
Prev Close72.86
Price73.32
Change %0.63%

Peers

Mkt cap
TickerCompanyMkt cap
COOCooper Companies Inc11.98B
ICUIICU Medical Inc4.46B
TFXTeleflex Incorporated6.19B
ANGOAngiodynamic Inc515.59M
LMATLemaitre Vascular Inc1.81B
MMSIMerit Medical Systems Inc5.26B
PDEXPro-Dex Inc228.83M
FEMYFemasys Inc12.57M
KRMDKORU Medical Systems Inc174.06M
RVPRetractable Technologies Inc16.53M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
CORNWELL KEVIN LChairman, CEOOct 29 '26Buy66.751,00066,750189,472Oct 29 04:46 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DESWisdomTree U.S. SmallCap Dividend FundAUM: 2.12B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
SFGVSequoia Global Value ETFAUM: 1.18B
DEEPAcquirers Small and Micro Deep Value ETFAUM: 25.47M

News

latest 14 of 200
  • Utah Medical Products, Inc. Increases Quarterly Dividend (ACCESSWIRE)
  • Utah Medical Products, Inc. Reports Corrected Results of Tender Offer (ACCESSWIRE)
  • Utah Medical Products, Inc. Reports Results of Tender Offer (ACCESSWIRE)
  • Utah Medical: Q3 Earnings Snapshot (Associated Press)
  • UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 (ACCESSWIRE)
  • Utah Medical Products, Inc. Extends Tender Offer (ACCESSWIRE)
  • Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date (ACCESSWIRE)
  • Utah Medical Products, Inc. Commences Tender Offer (ACCESSWIRE)
  • Utah Medical Products Inc's Dividend Analysis (GuruFocus.com)
  • UTMD Announces Self-Tender for 20% of Its Shares (ACCESSWIRE) +5.60%
  • Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK (ACCESSWIRE)
  • Utah Medical Products, Inc. Announces Quarterly Dividend (ACCESSWIRE)
  • Utah Medical: Q2 Earnings Snapshot (Associated Press) -7.24%
  • UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026 (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-04-23--0.8188.72--
2025Q42026-01-29--0.8029.04--
2025Q22025-07-24--0.9399.95--
2025Q12025-04-29--0.9199.71--
2024Q42025-01-28--0.8579.16--
2024Q32024-10-29--1.024---
2023Q42024-01-30--1.18112.33--
2023Q32023-10-26--1.081---
2023Q22023-07-25--1.154---
2023Q12023-04-25--1.15912.52--
2022Q12022-04-26--0.96412.32--
2021Q12021-04-22--0.82710.96--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2012FY2.7402.6902.74041.55-
2013FY3.0222.7253.02240.4940.00
2014FY3.0152.8403.01541.2841.20
2015FY3.140-3.14040.16-
2016FY3.220-3.22039.30-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual2.284.9513.9392.9414.044.5224.5743.9613.4833.3399
Period201720182019202020212022202320242025TTM
EPS, quarterly1.0240.8570.9190.9390.820.8020.8180.8440.876
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual41.41441.99846.90442.17849.05452.28150.22440.90338.5234.92
Period201720182019202020212022202320242025TTM
Sales, quarterly10.0059.1589.719.9539.8129.0458.7228.5298.621
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual3.7213.723.7223.6433.6553.6283.633.3353.1863.175
Period201720182019202020212022202320242025MRQ
Shares, quarterly3.4413.3353.2813.2163.2043.1863.1843.1833.175
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue34.9238.5240.9050.2252.2849.0542.1846.9042.00
Cost of Goods Sold Incl. D&A15.8218.6418.8225.8826.5024.7823.1423.5817.88
Gross Profit19.1019.8822.0824.3525.7824.2719.0323.3224.11
Selling, General and Administrative Excl. Other8.456.926.345.915.325.375.335.675.43
Research and Development0.660.670.810.560.490.530.490.480.45
Other Operating Expense-0.000.000.000.000.000.000.000.00
Operating Income10.6412.9515.7318.4420.4618.9013.7117.6518.69
Interest Expense-0.000.000.000.000.000.000.000.00
Unusual Expense-1.552.141.660.670.020.000.02-0.01
Net Income Before Taxes12.9714.1116.8020.0920.6619.0613.8417.8819.46
Income Taxes2.332.822.933.454.194.273.043.160.90
Consolidated Net Income10.6411.2913.8716.6416.4714.7910.8014.7318.55
Net Income From Continuing Operations10.6411.2913.8716.6416.4714.7910.8014.7318.55
Net Income10.6411.2913.8716.6416.4714.7910.8014.7318.55
EPS (Recurring)3.353.824.394.894.654.042.943.944.95
EPS (Basic, Before Extraordinaries)-3.483.964.584.534.052.953.964.97
EPS (Diluted)3.343.483.964.574.524.042.943.944.95
EBITDA12.5915.9618.5824.8027.5426.1920.9224.5321.64
Non-Operating Income (Expense)-0.302.713.213.310.870.180.130.250.76
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.300.290.200.180.140.170.120.080.05
Price To Earnings Ratio21.8221.8214.3718.1222.8824.7428.1626.8916.49
Price To Sales Ratio6.744.715.266.107.017.467.348.607.41
Gross Margin54.6951.6053.9848.4749.3149.4845.1349.7257.42
Operating Margin30.4933.6238.4636.7139.1338.5332.5037.6344.50
Net Margin30.4829.3033.9233.1231.5130.1525.6031.4044.18
Shares Outstanding3.183.193.343.633.633.653.643.723.72
Market Capitalization207.58207.58208.48305.68364.68365.09301.36394.26304.63

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue8.628.538.729.049.819.959.719.16
Cost of Goods Sold Incl. D&A3.823.793.904.314.754.904.684.35
Gross Profit4.804.744.824.735.065.065.034.81
Selling, General and Administrative Excl. Other2.012.092.252.102.451.861.881.88
Research and Development0.140.150.150.210.170.140.150.12
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income2.792.652.562.642.613.203.152.93
Interest Expense-0.000.000.000.000.000.000.00
Unusual Expense-0.000.000.200.000.000.000.00
Net Income Before Taxes3.403.293.183.113.313.843.863.61
Income Taxes0.610.600.580.540.680.790.820.71
Consolidated Net Income2.792.692.602.572.633.053.042.90
Net Income From Continuing Operations2.792.692.602.572.633.053.042.90
Net Income2.792.692.602.572.633.053.042.90
EPS (Recurring)0.880.840.820.850.820.940.920.86
EPS (Basic, Before Extraordinaries)-0.840.820.800.820.940.920.86
EPS (Diluted)0.880.840.820.800.820.940.920.86
EBITDA3.052.893.253.403.383.953.873.66
Non-Operating Income (Expense)0.610.640.62-2.160.700.640.70-2.70
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense0.060.060.090.090.080.070.060.06
Price To Earnings Ratio21.8220.4117.8115.8316.8415.0714.1814.37
Price To Sales Ratio6.746.085.264.655.234.764.725.09
Gross Margin55.7155.6055.2652.3151.5650.8051.7952.48
Operating Margin32.4231.0629.4129.1426.6132.1132.4731.99
Net Margin32.3331.4929.8628.3726.8130.6231.3231.69
Shares Outstanding3.183.183.183.193.203.223.283.34
Market Capitalization207.58219.63197.44179.28201.86184.89183.91208.48

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments85.7682.9892.8775.0560.9751.5942.7951.1139.95
Short Term Receivables3.524.093.395.545.134.104.743.963.62
Inventories7.938.819.588.816.606.226.915.415.24
Other Current Assets0.530.450.430.520.460.350.440.420.37
Total Current Assets97.7496.33106.2789.9273.1662.2654.8960.9049.19
Net Property, Plant & Equipment9.919.7610.5510.2211.0711.3310.7310.3611.62
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets14.8916.4518.6423.7331.4138.1644.1728.5131.94
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets122.54122.54135.46123.87115.64111.75109.7999.7792.75
Short Term Debt Incl. Current Port. of LT Debt0.060.060.050.050.050.040.040.000.00
Accounts Payable0.910.700.771.220.760.791.100.970.93
Income Tax Payable-0.91-0.150.330.340.040.000.510.841.26
Other Current Liabilities2.543.163.574.352.902.961.803.443.09
Total Current Liabilities2.603.764.715.963.753.793.455.265.28
Long Term Debt0.230.280.290.340.400.340.380.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.451.071.442.062.682.802.763.083.56
Other Liabilities0.000.000.701.261.682.002.112.445.79
Total Liabilities3.275.117.149.628.508.928.6910.7814.62
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity119.27117.43128.31114.25107.14102.82101.0988.9978.12
Total Shareholders Equity119.27117.43128.31114.25107.14102.82101.0988.9978.12
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity119.27117.43128.31114.25107.14102.82101.0988.9978.12
Total Liabilities & Stockholders Equity122.54122.54135.46123.87115.64111.75109.7999.7792.75
Book Value Per Share37.4335.2135.3531.4929.3128.2227.1623.9220.99
Tangible Book Value Per Share32.7630.2830.2124.9520.7217.7515.2916.2612.41
Full-Time Employees183173197227178181182173172
Price to Book Ratio1.881.702.473.373.412.933.903.413.66
Return on Assets9.2110.7612.8313.7613.019.7514.0619.2810.05
Return on Equity9.5411.2913.7214.8814.0910.5915.5022.2111.54
Return on Invested Capital9.4411.7912.9314.3713.7510.4714.5120.8510.89
Quick Ratio34.5723.2920.5313.6117.7714.7813.9110.558.32
Current Ratio37.6225.6422.5615.0919.5316.4215.9211.589.32

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-11.2913.8716.6416.4714.7910.8014.7318.55
Depreciation-3.012.856.377.087.287.216.882.96
Deferred Taxes & Investment Tax Credit--0.66-0.36-0.69-0.40-0.09-0.03-0.40-0.33
Other Funds (Non Cash)-0.740.270.200.220.230.160.17-0.31
Funds from Operations-14.3816.6322.5123.3722.2118.1421.3820.88
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.32-1.80-0.23-2.23-1.011.99-4.32-4.04
Cash from Operating Activities-14.6914.8322.2821.1521.2020.1417.0616.83
Capital Expenditures--0.37-0.23-0.64-0.82-0.55-0.86-21.54-0.40
Net Assets From Acquisitions-0.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses-0.000.030.000.000.000.000.000.86
Purchase or Sale of Investments-0.000.000.000.000.000.000.000.07
Purchase of Investments-0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.000.000.000.07
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities--0.37-0.21-0.64-0.82-0.55-0.86-21.540.53
Cash Dividends Paid--3.98-4.26-4.28-3.16-11.46-4.12-4.11-4.03
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Change in Capital Stock--8.36-19.580.12-2.320.56-6.62-0.12-0.75
Repurchase of Common Pref Stock--8.36-19.970.00-2.500.00-6.98-0.40-1.21
Sale of Common Pref Stock-0.000.390.120.170.560.360.280.45
Proceedsfrom Stock Options-0.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.000.000.000.00
Cash from Financing Activities--12.34-23.84-4.17-5.48-10.90-10.73-4.23-4.78
Exchange Rate Effect-0.80-0.680.34-0.77-0.360.260.39-1.35
Net Change in Cash-2.78-9.8917.8214.089.388.80-8.3211.24
Free Cash Flow-14.3214.6021.6420.3420.6519.2816.5216.43
Price to Free Cash Flow-17.5420.8217.6421.3239.8420.4232.5225.10

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments85.2087.5387.4185.7684.2782.18
Short Term Receivables3.963.563.643.523.733.63
Inventories10.579.008.727.938.128.23
Other Current Assets0.900.540.610.530.420.33
Total Current Assets100.63100.64100.3897.7496.5394.38
Net Property, Plant & Equipment10.029.639.729.9110.0010.26
Total Investments and Advances-0.000.000.000.000.00
Intangible Assets17.8414.3014.2814.8915.4416.17
Other Assets0.000.000.000.000.000.00
Total Assets128.50124.57124.38122.54121.97120.80
Short Term Debt Incl. Current Port. of LT Debt-0.000.000.060.000.00
Accounts Payable1.680.881.190.910.770.74
Income Tax Payable----0.91--
Other Current Liabilities3.061.192.312.542.241.52
Total Current Liabilities4.742.073.502.603.012.25
Long Term Debt0.180.200.210.230.240.26
Provision for Risks Charges-0.000.000.000.000.00
Deferred Tax Liabilities-0.270.290.450.470.76
Other Liabilities0.300.000.000.000.000.00
Total Liabilities5.222.544.013.273.723.27
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity123.28122.03120.37119.27118.25117.53
Total Shareholders Equity123.28122.03120.37119.27118.25117.53
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity123.28122.03120.37119.27118.25117.53
Total Liabilities & Stockholders Equity128.50124.57124.38122.54121.97120.80
Book Value Per Share38.8338.3437.8137.4336.9136.55
Tangible Book Value Per Share33.2133.8533.3232.7632.0931.52
Full-Time Employees---183--
Price to Book Ratio1.881.821.661.521.721.60
Return on Assets8.508.558.799.219.2410.01
Return on Equity8.818.759.149.549.5910.39
Return on Invested Capital2.262.202.162.152.222.59
Quick Ratio19.0044.2726.1534.5729.3638.22
Current Ratio21.2348.6228.6437.6232.0641.87

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-2.692.602.572.633.05
Depreciation-0.240.690.760.770.76
Other Funds (Non Cash)-0.070.120.080.500.09
Funds from Operations-2.973.253.393.623.74
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital--1.59-0.140.090.26-0.87
Cash from Operating Activities-1.383.113.483.882.87
Capital Expenditures--0.13-0.13-0.11-0.03-0.05
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.00
Purchase or Sale of Investments-0.000.000.000.000.00
Purchase of Investments-0.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.00
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities--0.13-0.13-0.11-0.03-0.05
Cash Dividends Paid--0.99-0.99-0.98-0.99-1.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock--0.08-0.13-0.99-0.65-3.49
Repurchase of Common Pref Stock--0.08-0.13-0.99-0.65-3.49
Sale of Common Pref Stock-0.000.000.000.000.00
Proceedsfrom Stock Options-0.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.00
Cash from Financing Activities--1.06-1.12-1.97-1.64-4.49
Exchange Rate Effect--0.06-0.210.09-0.120.52
Net Change in Cash-0.121.651.492.09-1.15
Free Cash Flow-1.252.983.373.852.82
Price to Free Cash Flow-29.2621.7817.3120.5319.07

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 40.90M 2025: 38.52M
United States2024: 40.90M 2025: 38.52M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.73%0.2M2.6M35.43K
2026-10-154.75%0.1M3.0M35.90K
2026-09-305.15%0.2M3.0M32.40K
2026-09-155.82%0.2M3.0M30.60K
2026-08-315.64%0.2M3.0M25.60K
2026-08-144.72%0.1M3.0M20.50K
2026-07-314.58%0.1M3.0M18.67K
2026-07-154.73%0.1M3.0M13.38K
2026-06-304.69%0.1M3.0M12.30K
2026-06-154.43%0.1M3.0M11.89K
2026-05-293.82%0.1M3.0M12.74K
2026-05-154.48%0.1M3.0M14.24K
2026-04-304.28%0.1M3.0M14.71K
2026-04-154.63%0.1M3.0M15.12K
2026-03-314.44%0.1M3.0M15.59K
2026-03-133.86%0.1M3.0M14.86K
2026-02-273.71%0.1M3.0M15.84K
2026-02-133.50%0.1M3.0M14.63K
2026-01-303.38%0.1M3.0M14.32K
2026-01-153.32%0.1M3.0M12.89K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-038-KCurrent report2026-11-03SEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-29SC TO-I/ASEC
2026-10-228-KCurrent report2026-10-22SEC
2026-10-05SC TO-I/ASEC
2026-09-29SC TO-I/ASEC
2026-09-25SC TO-CWritten communication relating to an issuer or third party tender offerSEC
2026-09-24SC TO-CWritten communication relating to an issuer or third party tender offerSEC
2026-09-24SC 13E3Schedule filed to report going private transactionsSEC
2026-09-17SC TO-CWritten communication relating to an issuer or third party tender offerSEC
2026-08-318-KCurrent report2026-08-31SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-238-KCurrent report2026-07-23SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-27SDSpecialized Disclosure ReportSEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-05-01SEC
2026-04-238-KCurrent report2026-04-23SEC
2026-04-02DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-02SEC
2026-03-2710-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-27SCHEDULE 13G/ASEC
2026-01-298-KCurrent report2026-01-29SEC
2025-12-183Initial statement of beneficial ownership of securities2025-10-31SEC
2025-11-254Statement of changes in beneficial ownership of securities2025-10-31SEC
2025-11-1410-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-11-048-KCurrent report2025-11-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1066.75K100
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BRANDES INVESTMENT PARTNERS, LP14.92%
DIMENSIONAL FUND ADVISORS LP6.42%
BlackRock, Inc.6.40%
RENAISSANCE TECHNOLOGIES LLC5.52%
VANGUARD CAPITAL MANAGEMENT LLC4.23%
Minerva Advisors LLC2.94%
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC2.68%
GEODE CAPITAL MANAGEMENT, LLC2.41%
RICE HALL JAMES & ASSOCIATES, LLC2.24%
MORGAN STANLEY2.19%

Funds

Fund% owned
Brandes Small Cap Value Fund6.87%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.07%
iShares Russell 2000 ETF2.12%
U.S. SMALL CAP VALUE PORTFOLIO1.15%
Fidelity Small Cap Index Fund1.06%
VANGUARD EXTENDED MARKET INDEX FUND1.05%
Fidelity Small-Mid Multifactor ETF1.00%
U.S. MICRO CAP PORTFOLIO0.95%
iShares Russell 2000 Value ETF0.89%
U.S. Targeted Value Portfolio0.68%

OakChart. UTMD. Cached 15 minutes.

Some panels did not load: ratings.